AZN vs JNJ
AstraZeneca PLC and Johnson & Johnson, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AZN | JNJ |
|---|---|---|
| Revenue | $58.7B | $94.2B |
| Net income | $10.2B | $26.8B |
| Gross margin | 81.9% | 67.9% |
| Net margin | 17.4% | 28.5% |
| Return on equity | 22.9% | 35.0% |
| Diluted EPS | $6.54 | $11.03 |
| Dividend / share | $3.13 | $5.14 |
| Payout ratio | 48.6% | · |
| Free cash flow | $11.8B | $19.7B |
| Equity | $48.7B | · |
| Net debt / equity | 0.49× | 0.27× |
| Current ratio | 0.94× | 1.03× |
| Revenue CAGR 5y | 17.2% | 2.7% |
| Profit CAGR 5y | 26.2% | 12.7% |
JNJ bills 1.6× the revenue of AZN, and keeps more of each dollar of revenue as profit (28.5% against 17.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AZN | JNJ |
|---|---|---|
| FY2025 | $58.7B | $94.2B |
| FY2024 | $54.1B | $88.8B |
| FY2023 | $45.8B | $85.2B |
| FY2022 | $44.4B | $80.0B |
| FY2021 | $37.4B | $78.7B |
| FY2020 | $26.6B | $82.6B |
| FY2019 | $24.4B | $82.1B |
| FY2018 | $22.1B | $81.6B |
| FY2017 | $22.5B | $76.5B |
| FY2016 | $23.0B | $71.9B |
Bottom line
| Fiscal year | AZN | JNJ |
|---|---|---|
| FY2025 | $10.2B | $26.8B |
| FY2024 | $7.0B | $14.1B |
| FY2023 | $6.0B | $35.2B |
| FY2022 | $3.3B | $17.9B |
| FY2021 | $112.0M | $20.9B |
| FY2020 | $3.2B | $14.7B |
| FY2019 | $1.3B | $15.1B |
| FY2018 | $2.2B | $15.3B |
| FY2017 | $3.0B | $1.3B |
| FY2016 | $3.5B | $16.5B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$35,454,000,000 | JNJ |
| FY2024 | −$34,748,000,000 | JNJ |
| FY2023 | −$39,348,000,000 | JNJ |
| FY2022 | −$35,639,000,000 | JNJ |
| FY2021 | −$41,323,000,000 | JNJ |
| FY2020 | −$55,967,000,000 | JNJ |
| FY2019 | −$57,675,000,000 | JNJ |
| FY2018 | −$59,491,000,000 | JNJ |
| FY2017 | −$53,985,000,000 | JNJ |
| FY2016 | −$48,888,000,000 | JNJ |
| FY2015 | −$45,366,000,000 | JNJ |
JNJ has reported the higher revenue in every one of these 11 fiscal years. The gap has narrowed since the earliest year compared.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −11.0 pp | JNJ |
| FY2024 | −2.8 pp | JNJ |
| FY2023 | −28.3 pp | JNJ |
| FY2022 | −15.0 pp | JNJ |
| FY2021 | −26.2 pp | JNJ |
| FY2020 | −6.0 pp | JNJ |
| FY2019 | −13.4 pp | JNJ |
| FY2018 | −9.5 pp | JNJ |
| FY2017 | +11.1 pp | AZN |
| FY2016 | −8.2 pp | JNJ |
| FY2015 | −10.6 pp | JNJ |
The higher net margin has changed hands between AZN and JNJ over this period.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
JNJ's net margin has been more volatile than AZN's over the 11 comparable fiscal years — 9.2 percentage points of standard deviation against 4.6.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AZN and JNJ over these 11 fiscal years — AZN led in 1 and JNJ in 10.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
JNJ's return on equity has been more volatile than AZN's over the 11 comparable fiscal years — 10.6 percentage points of standard deviation against 6.4.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AZN and JNJ over these 11 fiscal years — AZN led in 1 and JNJ in 10.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.